Free Trial
→ Trump’s national nightmare is here (From Porter & Company) (Ad)tc pixel

Short Interest in Genmab A/S (OTCMKTS:GNMSF) Drops By 56.4%

Written by MarketBeat
Updated August 22, 2025
Genmab A/S logo with Medical background

Key Points

  • Short interest in Genmab A/S dropped by 56.4% in July, with total shares short decreasing from 69,900 to 30,500.
  • The company's stock price rose by 7.4%, reaching $232.30, and the stock has a market capitalization of $15.35 billion.
  • Genmab's latest quarterly earnings report showed earnings per share of $5.42, exceeding analysts' expectations, despite revenue falling short of estimates at $925 million.
  • Interested in Genmab A/S? Here are five stocks we like better.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totaling 30,500 shares, adeclineof56.4% from the July 15th total of 69,900 shares. Approximately0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 305.0 days. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 305.0 days. Approximately0.0% of the shares of the stock are sold short.

Genmab A/S Stock Up 1.4%

Shares of Genmab A/S stock traded up $3.3705 on Friday, reaching $244.35. The company's stock had a trading volume of 266 shares, compared to its average volume of 544. Genmab A/S has a 52-week low of $170.00 and a 52-week high of $282.06. The company has a market capitalization of $16.15 billion, a P/E ratio of 12.27 and a beta of 0.93. The stock has a 50-day moving average price of $217.14 and a 200-day moving average price of $208.39.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $949.06 million.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.